Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Polypharmacy and acute kidney function impairment after starting bempedoic acid
Anno:
2025
Background. Bempedoic acid is an established treatment for dyslipidemia. In randomized clinical trial the treatment with bempedoic acid was associated with a small increase in creatinine levels. We present the  case of a patient with chronic coronary syndrome, heart failure with mild reduction of ejection fraction, and dyslipidemia with…
Leggi di più
TRIPLE ORAL COMBINATION TO LOWER LDL-C IN A PATIENT WITH POLYVASCULAR DISEASES
Anno:
2025
Patients with Peripheral Artery Disease are at increased risk of atherosclerotic cardiovascular (CV) events with high rate of recurrence. Bempedoic acid is a therapeutical option for the management of patients with hypercholesterolemia approved by EMA in 2020 and available in Italy since 2023.   We report the case of…
Leggi di più
Anti-Inflammatory properties of Semaglutide: A Systematic Review and Meta-Analysis
Anno:
2025
Background: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated efficacy in reducing the risk of adverse cardiovascular events in patients with type 2 diabetes mellitus (T2DM) who are at high cardiovascular risk or have established cardiovascular disease. Aim: This analysis aims to evaluate the anti-inflammatory effects of semaglutide…
Leggi di più
EFFECT OF BEMPEDOIC ACID ADDED TO STANDARD HYPOLIPIDEMIC THERAPY ON LIPID TAGET ACHIEVEMENT AND VARIABILITY OF LDL-C VALUES IN HIGH RISK PATIENTS.
Anno:
2025
Background: Low-density lipoprotein cholesterol (LDL-C) variability could be related to increased cardiovascular risk in patients already treated with statins. Bempedoic acid (BA) is approved for the reduction of LDL-C in addition to or instead of statin therapy and ezetimibe.  Aim: to assess impact of BA addition to statin therapy…
Leggi di più
A NATIONAL PROJECT TO IMPROVE THE QUALITY OF SECONDARY PREVENTION STRATEGIES: THE RESULTS OF THE BRING-UP PREVENTION STUDY
Anno:
2025
Background. Adherence to guideline recommendations for secondary prevention strategies appears to be largely inadequate. Aim. To try to narrow the gap between what is recommended and what is implemented in clinical practice, we designed a national implementation science project, BRING-UP Prevention, based on educational programmes and patient data collection….
Leggi di più
CLINICAL IMPLEMENTATION O BEMPEDOIC ACID IN BLOOD LIPID MANAGEMENT: REAL-WORRLD DATA FROM AN ITALIAN LIPID CLINIC
Anno:
2025
Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), and  lipid-lowering therapies (LLT) are critical for reducing morbidity and mortality. Despite the widespread use of statins (ST) and other LLT agents, a significant proportion of patents (Pts) fails to achieve target lipid levels due to inadequate response,…
Leggi di più
STATIN INTOLERANCE IN A REAL WORD SETTING OF ITALIAN CARDIOLOGY CENTERS: DATA FROM THE BRING-UP PREVENTION STUDY
Anno:
2025
Background. Statins are commonly prescribed to prevent cardiovascular disease by lowering low-density lipoprotein cholesterol (LDL-C). However, statin intolerance can limit their use or adherence to optimal high-intensity statin therapy. Observational studies have estimated intolerance in 25-30% of patients, while the prevalence in randomised clinical trials has been largely lower….
Leggi di più
SECONDARY PREVENTION IN PATIENTS AT EXTREME CARDIOVASCULAR RISK: WHAT CAN WE DO MORE?
Anno:
2025
Prevalence of Heterozygous Familial Hypercholesterolemia (FH) is estimated to be around 1/200-250, which corresponds to 14-34 million cases worldwide. A 27 years-old man was referred to our clinic because of exercise angina. He had a total cholesterol (TC) of 379 mg/dl, HDL 38 mg/dl, LDL 330 mg/dl and TG…
Leggi di più
The future of lowering triglycerides therapy in secondary cardiovascular prevention: insights from the JET-LDL Registry
Anno:
2025
Rational Hypertriglyceridemia is a common finding in patients with coronary artery disease (CAD), contributing to the residual cardiovascular risk in this population. In CAD patients with persistently elevated triglycerides levels despite lipid lowering therapies, a treatment with icosapent ethyl (IPE), compared to placebo, significantly lowered the risk of ischemic…
Leggi di più
EFFECTIVENESS OF RENAL DENERVATION IN HIGH RISK PATIENTS WITH RESISTANT HYPERTENSION
Anno:
2025
Background: Recent trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN) as nonpharmacological treatment in resistant hypertension  in the presence of concomitant antihypertensive therapy. Aim: we report data of preliminary experience with RDN (Symplicity Spyral renal denervation system, Medtronic Inc.) in patients with resistant hypertension and…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram